0MPT.IL - Brenntag SE
IOB - IOB Prezzo differito. Valuta in EUR.
Al 12:17PM BST. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
| Chiusura precedente | 75,58 |
| Aperto | 76,08 |
| Denaro | 74,70 x 0 |
| Lettera | 76,30 x 0 |
| Min-Max giorno | 75,30 - 76,08 |
| Intervallo di 52 settimane | 53,64 - 77,62 |
| Volume | |
| Media Volume | 324.204 |
| Capitalizzazione | 11,635B |
| Beta (5 anni mensile) | 1,06 |
| Rapporto PE (ttm) | 13,66 |
| EPS (ttm) | 5,53 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 2,00 (2,66%) |
| Data ex dividendo | 16 giu 2023 |
| Stima target 1A | N/D |
GlobeNewswireDr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that collaborator Brahm Segal, M.D., of Roswell Park Comprehensive Cancer Center shared nonclinical data from a research study that models the ability of NC410 to block neutrophil-mediated suppression of T cells in a tumor microen